 |
|
 |
|
 |
|
 |
|
 |
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
 |
|
 |
|
2008 Events Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse™ a Local Anesthetic Reversal Agent |
Novalar™ Receives FDA Approval for OraVerse™ |
2007 Events Novalar™ Strengthens Senior Management Team with Key Appointments. |
Novalar™ Raises $30 Million in Series D Financing. |
Novalar™ Appoints Steven J. Semmelmayer to its Board of Directors. |
Novalar™ announces exclusive license to develop and commercialize antibiotic fiber for root canal therapy. |
Novalar™ announces acceptance of OraVerse New Drug Application for filing by FDA. |
Novalar™ hires Vice President of Marketing to direct launch of anesthetic reversal agent OraVerse. |
Novalar™ submits New Drug Application for anesthetic reversal agent OraVerse.
|
Novalar™ presents results from successful studies of anesthetic reversal agent at International Association of Dental Research Annual Meeting. |
2006 Events Novalar’s™ Positive Phase 2 Pediatric Study Results Support Recent Pivotal Data in Adolescents and Adults. |
Novalar™ Announces Positive Phase 3 Results for Novel Dental Anesthesia Reversal Agent. |
Novalar™ Initiates Pivotal Phase 3 Studies for Novel Dental Anesthesia Reversal Agent. |
2005 Events Novalar Pharmaceuticals™ Raises $27 Million in Series C Financing. |
2004 Events CEO, VP Development and VP Clinical Operations join Novalar Pharmaceuticals team. |
2003 Events Novalar starts Phase 2 studies on its first product, OraVerse. |
2002 Events Novalar Pharmaceuticals obtains initial funding. Phase 1b/2a Dose Range Finding |
2000 Events Novalar Pharmaceuticals founded. |
